KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Operating Leases (2019 - 2025)

Historic Operating Leases for Nektar Therapeutics (NKTR) over the last 7 years, with Q3 2025 value amounting to $69.7 million.

  • Nektar Therapeutics' Operating Leases fell 1962.47% to $69.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $69.7 million, marking a year-over-year decrease of 1962.47%. This contributed to the annual value of $82.7 million for FY2024, which is 1605.92% down from last year.
  • Latest data reveals that Nektar Therapeutics reported Operating Leases of $69.7 million as of Q3 2025, which was down 1962.47% from $74.1 million recorded in Q2 2025.
  • Nektar Therapeutics' Operating Leases' 5-year high stood at $134.6 million during Q1 2021, with a 5-year trough of $69.7 million in Q3 2025.
  • Moreover, its 5-year median value for Operating Leases was $105.8 million (2023), whereas its average is $104.5 million.
  • Its Operating Leases has fluctuated over the past 5 years, first tumbled by 544.0% in 2021, then crashed by 1962.47% in 2025.
  • Nektar Therapeutics' Operating Leases (Quarter) stood at $125.7 million in 2021, then dropped by 10.27% to $112.8 million in 2022, then fell by 12.68% to $98.5 million in 2023, then dropped by 16.06% to $82.7 million in 2024, then dropped by 15.68% to $69.7 million in 2025.
  • Its last three reported values are $69.7 million in Q3 2025, $74.1 million for Q2 2025, and $78.5 million during Q1 2025.